Living Cell Technologies Reports On 12-Month Clinical Effects Of DiabeCell® At Annual General Meeting Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today updated shareholders at their Annual General Meeting in Adelaide, Australia on the Phase I/IIa clinical trial of DiabeCell®, LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes. A total of six patients have been implanted with DiabeCell® to date; five patients received the lowest dose of 5,000 islet equivalents (IEQ/kg), and one patient was dosed with 10,000 IEQ/kg.
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 PM
